Evicenter
MarkdownMedical informationP&T meetings
Lysergide (DT120)

Generalized anxiety disorder

Also known as MM120
Launch
Not announced
Last updated
199 sources

Executive summary

Burden of Generalized anxiety disorder

1 evidence topic · 13 sources

Summary

The Mental and Substance Use Disorders Prevalence Study, which interviewed close to 5,700 U.S. adults aged 18 to 65 between October 2020 and October 2022, reported a past-year prevalence of generalized anxiety disorder (GAD) of 10.0% (95% CI 8.3% to 12.1%), approximately 20.2 million adults; its report names the study's conduct during the COVID-19 pandemic as the most obvious explanation for rates higher than in past nationally representative studies. Other estimates of 12-month prevalence are 2.7% of U.S. adults aged 18 or older in the National Comorbidity Survey Replication, 3.1% in a second analysis of that survey, and 2.1% in a third study, which reported a lifetime prevalence of 4.1%. In U.S. claims of adults engaging with the healthcare system, projected annual prevalence of diagnosed GAD rose from 5.4% in 2020 to 6.6% in 2023, and annual incidence of newly diagnosed GAD ranged from 2.1% to 2.3%. A further study reported a 1-year incidence of DSM-IV GAD of 1.12 per 100 person-years at risk. Definium Therapeutics states that GAD affects approximately 26 million U.S. adults, citing the prevalence study, Census data, and internal company estimates.

Over 12 years of follow-up, patients with GAD had a recovery probability of 0.58 and a recurrence probability after recovery of 0.45. Worldwide, lifetime comorbidity was 81.9%, with major depressive disorder in 52.6% of lifetime cases. Compared with the general population, mortality rate ratios in GAD were 1.62 (95% CI 1.35 to 1.93) for all causes and 2.55 (2.00 to 3.19) for unnatural causes.

In the 2022 US National Health and Wellness Survey, adjusted EQ-5D index scores were 0.80, 0.75, and 0.66 in mild, moderate, and severe GAD against 0.84 in controls. Adjusted total direct costs were $11,711 in diagnosed and $18,045 in undiagnosed GAD against $9,190 without GAD, and indirect costs were $7,507, $7,805, and $6,532, respectively. Of U.S. adults with past-year GAD, 32.3% had serious impairment.